Karine Lacombe, Raoul Moh, Corine Chazallon, Maud Lemoine, Babacar Sylla, Fatoumata Fadiga, Jerôme Le Carrou, Fabienne Marcellin, Charles Kouanfack, Laura Ciaffi, Michelle Tagni Sartre, Magloire Biwole Sida, Alpha Diallo, Joel Gozlan, Moussa Seydi, Viviane Cissé, Christine Danel, Pierre Marie Girard, Thomas d'Aquin Toni, Albert Minga, Sylvie Boyer, Patrizia Carrieri, Alain Attia
Access to Hepatis C treatment in Sub-Saharan Africa is a clinical, public health and ethical concern. The multi-country open-label trial TAC ANRS 12311 allowed assessing the feasibility, safety, efficacy of a specific care model of HCV treatment and retreatment in patients with hepatitis C in Sub Saharan Africa. Between November 2015 and March 2017, with follow-up until mid 2019, treatment-naïve patients with HCV without decompensated cirrhosis or liver cancer were recruited to receive 12 week-treatment with either sofosbuvir + ribavirin (HCV genotype 2) or sofosbuvir + ledipasvir (genotype 1 or 4) and retreatment with sofosbuvir + velpatasvir + voxilaprevir in case of virological failure...
May 3, 2024: Scientific Reports